Patrys Ltd has released a press release.
New PAT-DX3 data demonstrates synthetic lethality
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Patrys
- Appendix 4D - Half Year Accounts - 31 December 2022
- Appendix 4C - Quarterly - 31 December 2022
- Response to ASX Price Query
- Patrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy
- Appendix 4C - Quarterly - 30 September 2022
Later from Patrys
- Updated guidance for PAT-DX1 phase 1 clinical study
- Two new deoxymab patents granted in the USA
- Patrys secures US patents for antibody technology
- Appendix 4C - Quarterly - 31 March 2023
- PAT-DX1 GLP toxicology reports received
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys